Acurx Pharmaceuticals (ACXP) Accumulated Expenses (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Accumulated Expenses came in at $3374.0 in Q1 2026, down 0.59% YoY from $3394.0 in Q1 2025, and down 50.4% on a QoQ basis from $6802.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Accumulated Expenses (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Accumulated Expenses data on file, last reported at $3374.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 0.59% year-over-year to $3374.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3374.0 (down 0.59% YoY) and the FY2025 annual result came in at $6802.0, up 42.09% from the prior year.
- Accumulated Expenses declined to $3374.0 in Q1 2026, from $6802.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $3.0 million in Q2 2024 to a low of $3374.0 in Q1 2026.
- A 5-year average of $410372.9 and a median of $18413.0 in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 8193.75% — and 2025, when it sank 99.85%.
- Tracing ACXP's Accumulated Expenses over 5 years: stood at $29539.0 in 2022, then tumbled by 87.11% to $3809.0 in 2023, then gained by 25.68% to $4787.0 in 2024, then jumped by 42.09% to $6802.0 in 2025, then slumped by 50.4% to $3374.0 in 2026.
- The last three Accumulated Expenses figures came in at $3374.0 (Q1 2026), $6802.0 (Q4 2025), and $52710.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acurx Pharmaceuticals | 6.38 Mn | 6.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77 Mn |
| Mar 31, 2026 | 3,374.00 |
| Dec 31, 2025 | 6,802.00 |
| Sep 30, 2025 | 52,710.00 |
| Jun 30, 2025 | 4,436.00 |
| Mar 31, 2025 | 3,394.00 |
| Dec 31, 2024 | 4,787.00 |
| Sep 30, 2024 | 19,097.00 |
| Jun 30, 2024 | 2.98 Mn |
| Mar 31, 2024 | 9,202.00 |
| Dec 31, 2023 | 3,809.00 |
| Sep 30, 2023 | 2.97 Mn |
| Jun 30, 2023 | 35,887.00 |
| Mar 31, 2023 | 18,413.00 |
| Dec 31, 2022 | 29,539.00 |
| Sep 30, 2022 | 296,655.00 |
| Jun 30, 2022 | 5,764.00 |
| Mar 31, 2022 | 532,322.00 |
| Dec 31, 2021 | 63,374.00 |
| Sep 30, 2021 | 252,117.00 |